Latest & greatest articles for cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cancer

8481. Surveillance mammography after treatment for primary breast cancer

Surveillance mammography after treatment for primary breast cancer Surveillance mammography after treatment for primary breast cancer Surveillance mammography after treatment for primary breast cancer McGahan L, Noorani HZ Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation McGahan L, Noorani HZ. Surveillance mammography after treatment (...) for primary breast cancer. Ottawa: Canadian Coordinating Office for Health Technology Assessment/Office Canadien de Coordination de l'Evaluation des Technologies de la Sante (CCOHTA) 2000: 17 Authors' objectives This review aims to evaluate the practice of routine surveillance mammography and its impact on disease outcomes. Authors' conclusions Considerable controversy exists regarding the frequency and intensity of surveillance following treatment for breast cancer. This paper is a systematic, structured

Health Technology Assessment (HTA) Database.2000

8482. Guidance on the use of taxanes for ovarian cancer

Guidance on the use of taxanes for ovarian cancer Guidance on the use of taxanes for ovarian cancer Guidance on the use of taxanes for ovarian cancer National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Clinical Excellence. Guidance on the use of taxanes for ovarian cancer. London: National Institute (...) for Clinical Excellence (NICE). Technology Appraisal Guidance 3. 2000 Authors' objectives To provide guidance on the use of taxanes for the treatment of ovarian cancer. Authors' conclusions Guidance 1.1 Paclitaxel in combination with a platinum therapy (cisplatin or carboplatin) should be the standard initial therapy for patients with ovarian cancer following surgery. 1.2 The use of paclitaxel/platinum combination therapy in the treatment of recurrent (or resistant) ovarian cancer is recommended

Health Technology Assessment (HTA) Database.2000

8483. Brachytherapy and prostate cancer

Brachytherapy and prostate cancer Brachytherapy and prostate cancer Brachytherapy and prostate cancer Conseil d'Evaluation des Technologies de la Sante du Quebec Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Conseil d'Evaluation des Technologies de la Sante du Quebec. Brachytherapy and prostate cancer. Montreal: Conseil d'Evaluation des (...) Technologies de la Sante du Quebec (CETS). CETS 99-5 RF. 2000 Authors' objectives This study aims summarise the available evidence on the use of brachytherapy in the treatment of prostate cancer. It summarises the evidence of brachytherapy's intended and unintended effects and compares these to treatments in current use. Authors' conclusions This report concludes that the evidence is too weak to demonstrate either greater efficacy of brachytherapy compared to other treatments or better cost-effectiveness

Health Technology Assessment (HTA) Database.2000

8484. Clinical practice guidelines for the management of advanced breast cancer

Clinical practice guidelines for the management of advanced breast cancer

Cancer Australia2000

8486. Presymptomatic diagnosis of hereditary breast cancer

Presymptomatic diagnosis of hereditary breast cancer Presymptomatic diagnosis of hereditary breast cancer We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Swedish Agency for Health Technology Assessment and Assessment of Social Services Presymptomatic diagnosis of hereditary breast cancer Share: Reading time approx. 3 minutes This document was published more than 2 years ago. The nature of the evidence may have changed. Findings (...) by SBU Alert This is a translation of version 1, published on February 2, 2000. The latest version of this report is not available in English. The discovery that mutations in two specific genes increase the risk for breast cancer and ovarian cancer has opened new opportunities to prevent hereditary cancer. Special programs to identify, investigate, follow up, and treat individuals with hereditary breast cancer are being developed in Sweden. There is good* evidence that certain genes are associated

Swedish Council on Technology Assessement2000

8487. Lymphatic mapping and sentinel node biopsy in breast cancer

Lymphatic mapping and sentinel node biopsy in breast cancer Lymphatic mapping and sentinel node biopsy in breast cancer We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Swedish Agency for Health Technology Assessment and Assessment of Social Services Lymphatic mapping and sentinel node biopsy in breast cancer Share: Reading time approx. 3 minutes This document was published more than 2 years ago. The nature of the evidence may (...) have changed. Findings by SBU Alert This is a translation of version 2, published on September 15, 2000. The latest version of this report is not available in English. Breast cancer surgery always includes an investigation to determine whether cancer has spread to the axillary lymph nodes. In addition to removing the tumor itself, traditional treatment also includes removing several of the axially lymph nodes, for both diagnostic and therapeutic reasons. The intervention carries a substantial risk

Swedish Council on Technology Assessement2000

8488. Human papillomavirus testing in primary cervical cancer screening</a>

Human papillomavirus testing in primary cervical cancer screening Human papillomavirus testing in primary cervical cancer screening We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Swedish Agency for Health Technology Assessment and Assessment of Social Services Human papillomavirus testing in primary cervical cancer screening Share: Reading time approx. 3 minutes This document was published more than 2 years ago. The nature (...) of the evidence may have changed. Findings by SBU Alert Version: 1 Method and target group Approximately 800 000 cell tests are done annually in Sweden for the detection of potentially invasive cervical cancer in their preinvasive stages. These tests are performed both within and outside of the framework of organized screening programs and are referred to as primary screening. Furthermore, a large number of tests are performed in the further investigation of cervical intraepithelial neoplasias (CIN). Certain

Swedish Council on Technology Assessement2000

8489. Brachytherapy for prostate cancer

Brachytherapy for prostate cancer Brachytherapy for prostate cancer We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Swedish Agency for Health Technology Assessment and Assessment of Social Services Brachytherapy for prostate cancer Share: Reading time approx. 4 minutes This document was published more than 2 years ago. The nature of the evidence may have changed. Findings by SBU Alert This is a translation of version 1 (...) , published on February 2, 2000. The latest version of this report is not available in English. Brachytherapy is not widely used in Sweden to treat localized prostate cancer. This treatment method has been available for some time, but recent advancements in technology are leading to increased utilization. Findings from isolated, uncontrolled studies of high dose rate brachytherapy in combination with external beam radiotherapy suggest some improvement in treatment outcomes. However, prospective

Swedish Council on Technology Assessement2000

8491. A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer

A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page

NIHR HTA programme2000

8492. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group.

Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. 10683002 2000 03 02 2000 03 02 2015 06 16 0140-6736 355 9203 2000 Feb 12 Lancet (London, England) Lancet Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC (...) Radiotherapy Group. 528-33 Ductal carcinoma in situ (DCIS) of the breast is a disorder that has become more common since it may manifest as microcalcifications that can be detected by screening mammography. Since selected women with invasive cancer can be treated safely with breast conservation therapy it is paradoxical that total mastectomy has remained the standard treatment for DCIS. We did a randomised phase III clinical trial to investigate the role of radiotherapy after complete local excision

Lancet2000

8493. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group.

Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. 10760307 2000 04 13 2000 04 13 2013 11 21 0028-4793 342 15 2000 Apr 13 The New England journal of medicine N. Engl. J. Med. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone (...) Marrow Transplant Group. 1069-76 We conducted a randomized trial in which we compared high-dose chemotherapy plus hematopoietic stem-cell rescue with a prolonged course of monthly conventional-dose chemotherapy in women with metastatic breast cancer. Women 18 to 60 years of age who had metastatic breast cancer received four to six cycles of standard combination chemotherapy. Patients who had a complete or partial response to induction chemotherapy were then randomly assigned to receive either a single course of high

NEJM2000

8494. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study.

Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. 11052580 2001 09 07 2001 09 13 2015 06 16 0140-6736 356 9239 2000 Oct 21 Lancet (London, England) Lancet Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised (...) trial. Scandinavian Breast Group 9401 study. 1384-91 Chemotherapy drug distribution varies greatly among individual patients. Therefore, we developed an individualised fluorouracil, epirubicin, cyclophosphamide (FEC) regimen to improve outcomes in patients with high-risk early breast cancer. We then did a randomised trial to compare this individually tailored FEC regimen with conventional adjuvant chemotherapy followed by consolidation with high-dose chemotherapy with stem-cell support. 525 women

Lancet2000

8495. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial.

Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. 11145492 2000 12 28 2001 01 18 2015 11 19 0140-6736 356 9247 2000 Dec 16 Lancet (London, England) Lancet Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. 2059-63 Hot flashes can be troublesome, especially when hormonal therapy is contraindicated. Preliminary data have suggested that newer antidepressants, such as venlafaxine, can diminish (...) hot flashes. We undertook a double-blind, placebo-controlled, randomised trial to assess the efficacy of venlafaxine in women with a history of breast cancer or reluctance to take hormonal treatment because of fear of breast cancer. Participants were assigned placebo (n=56) or venlafaxine 37.5 mg daily (n=56), 75 mg daily (n=55), or 150 mg daily (n=54). After a baseline assessment week, patients took the study medication for 4 weeks. All venlafaxine treatment started at 37.5 mg daily and gradually

Lancet2000

8496. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. 10744089 2000 04 11 2000 04 11 2016 11 24 0140-6736 355 9209 2000 Mar 25 Lancet (London, England) Lancet Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. 1041-7 Irinotecan is active against colorectal cancer in patients whose (...) disease is refractory to fluorouracil. We investigated the efficacy of these two agents combined for first-line treatment of metastatic colorectal cancer. 387 patients previously untreated with chemotherapy (other than adjuvant) for advanced colorectal cancer were randomly assigned open-label irinotecan plus fluorouracil and calcium folinate (irinotecan group, n=199) or fluorouracil and calcium folinate alone (no-irinotecan group, n=188). Infusion schedules were once weekly or every 2 weeks, and were

Lancet2000

8497. Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians' Network.

Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians' Network. 10770980 2000 04 20 2000 04 20 2015 11 19 0028-4793 342 16 2000 Apr 20 The New England journal of medicine N. Engl. J. Med. Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians' Network. 1156-62 The risks of colorectal cancer and adenoma, the precursor lesion, are believed (...) to be influenced by dietary factors. Epidemiologic evidence that cereal fiber protects against colorectal cancer is equivocal. We conducted a randomized trial to determine whether dietary supplementation with wheat-bran fiber reduces the rate of recurrence of colorectal adenomas. We randomly assigned 1429 men and women who were 40 to 80 years of age and who had had one or more histologically confirmed colorectal adenomas removed within three months before recruitment began to a supervised program of dietary

NEJM2000

8498. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial.

Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial. 10874063 2000 06 29 2000 06 29 2013 11 21 0028-4793 342 26 2000 Jun 29 The New England journal of medicine N. Engl. J. Med. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial. 1953-8 The length of time after an episode of venous thromboembolism during which the risk of newly diagnosed cancer (...) is increased is not known, and whether vitamin K antagonists have an antineoplastic effect is controversial. In a prospective, randomized study of the duration of oral anticoagulation (six weeks or six months) after a first episode of venous thromboembolism, patients were questioned annually about any newly diagnosed cancer. After a mean follow-up of 8.1 years, we used the Swedish Cancer Registry to identify all diagnoses of cancer and causes of death in the study population. The observed numbers of cases

NEJM2000

8499. Comparison of flourouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. QUASAR Collaborative Group.

Comparison of flourouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. QUASAR Collaborative Group. 10821362 2000 06 07 2000 06 07 2015 06 16 0140-6736 355 9215 2000 May 06 Lancet (London, England) Lancet Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. QUASAR Collaborative Group. 1588-96 Standard (...) adjuvant chemotherapy for colorectal cancer consists of fluorouracil with folinic acid or levamisole. The large QUASAR randomised trial aimed to investigate (in a two x two design) whether use of a higher dose of folinic acid or addition of levamisole to fluorouracil and folinic acid improved survival. Patients with colorectal cancer, without evident residual disease, were randomly assigned fluorouracil (370 mg/m2) with high-dose (175 mg) or low-dose (25 mg) L-folinic acid and either active or placebo

Lancet2000

8500. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. 11006366 2000 09 28 2000 09 28 2016 11 24 0028-4793 343 13 2000 Sep 28 The New England journal of medicine N. Engl. J. Med. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. 905-14 The combination of fluorouracil and leucovorin has until recently been standard therapy for metastatic colorectal cancer. Irinotecan prolongs survival in patients (...) with colorectal cancer that is refractory to treatment with fluorouracil and leucovorin. In a multicenter trial, we compared a combination of irinotecan, fluorouracil and leucovorin with bolus doses of fluorouracil and leucovorin as first-line therapy for metastatic colorectal cancer. A third group of patients received irinotecan alone. Patients were randomly assigned to receive irinotecan (125 mg per square meter of body-surface area intravenously), fluorouracil (500 mg per square meter as an intravenous

NEJM2000